BUTTERBUR

Clinical evidence has mostly been in reducing the incidence and severity of migraines, supported by tts ability to penetrate the blood brain barrier combined witn anti-inflammatory actions. Commercial brands include Petadolex, which also showed efficacy in suppressing some symptoms of asthma.

Some studies have shown actions in reducing effects of seasonal allergy, with results similar to antihistamines. Butterbur has also been successfully used in a herbal anti-anxiety trial combined with valerian, lemon balm, passionflower  (see References)

TYPICAL ABSORPTION LEVELS

20 – 30%

EXAMPLES OF IMPROVED OUTCOMES

NO

PRE-DIAGNOSIS OR PREVENTION

Highlighted Studies

In vitro methods [test tube]including a cell proliferation assay and cell cycle analysis, were used to demonstrate that PJE induces apoptosis and suppresses the Akt/mTOR and Wnt signaling pathways by reducing the expression levels of β-catenin, p-Akt, p-mTOR and p-GSK3β. In addition, the in vivo experiments further confirmed that PJE suppressed the Akt/mTOR and Wnt signaling pathways. Therefore, these observations highlight the potential value of PJE as an anticancer agent...

Link

..Given that PT-mediated ETCC1 inhibition simultaneously disrupted multiple metabolism essential for tumor growth and metastasis, such a strategy could provide a better chance to conquer metastatic tumors that have heterogeneous molecular backgrounds and thus are resistant to conventional single molecule–targeted therapy…PT has a unique chemical structure and high potency, it may serve as a lead compound to develop a novel family of potent and less toxic ETCC1 inhibitors for treating ...

Link

Over 4 months of treatment, in the per-protocol analysis, migraine attack frequency was reduced by 48% for Petasites extract 75 mg bid (p = 0.0012 vs placebo), 36% for Petasites extract 50 mg bid (p = 0.127 vs placebo), and 26% for the placebo group. The proportion of patients with a > or =50% reduction in attack frequency after 4 months was 68% for patients in the Petasites extract 75-mg arm and 49% for the placebo arm (p < 0.05). Results were also significant in favor of Petasites 75 ...

Link

..standardized Petasites hybridus L. root extract induces oxidative stress and promotes a strong apoptotic response most likely, at least in part, as a result of elevated NF-<span id="MathJax-Element-228-Frame" class="mjx-chtml MathJax_CHTML" style="display: inline-block;line-height: 0;text-indent: 0px;text-align: left;text-transform: none;font-style: normal;font-weight: normal;font-size: 20.6px;letter-spacing: normal;float: none;direction: ltr;max-width: none;max-height: none;min-wid...

Link
BACK TO INDEX

TABLE OF REFERENCES

Help grow the evidence. Login and use the form, or try Feedback and Ideas below.

URLRatingHighlightHighlight 2Visuals (click)
https://www.bmj.com/content/324/7330/1441.5Although the effects of butterbur have been linked to its constituents,6–8 we set out to test whether its clinical effects in seasonal allergic rhinitis were comparable to those of antihistamines as judged separately and blindly by patients and their doctors. The results showed that the effects of the two treatments are similar. The trends in favour of butterbur in some measures need to be confirmed in future prospective trials. With regard to safety, butterbur was well tolerated and did not have the sedative effects associated with antihistamines. Fatigue and drowsiness accounted for two thirds of adverse events reported in the antihistamine group.We have no data on whether the efficacy and tolerability of continued treatment with butterbur would be similar to antihistamines. However, treatment for this condition is usually relatively short, being restricted to peaks in pollen count during the spring and early summer. We believe butterbur should be considered for treating seasonal allergic rhinitis, particularly in cases where the sedative effects of antihistamines need to be avoided.
https://www.anaturalhealingcenter.com/documents/Thorne/articles/petasites_asthma9-1.pdf1.5more than 40 percent of patients using asthma medications at baseline reduced intake of these medications by the end of the study. This study suggests the Petasites hybridus extract Petadolex is an effective and safe therapy for the treatment of asthma.Subjects who took Petadolex capsules also noted a mean 50-percent, self-reported improvement in documented asthma symptoms after two months of treatment. Although in the final two months the use of Petasites extract capsules was optional, one-half of the patients continued taking the extract. Compared to week 8, the severity of symptoms decreased further in the group remaining on Petadolex
https://pmc.ncbi.nlm.nih.gov/articles/PMC7317844/1.5 Because less patients received concomitant prescriptions of benzodiazepines among the cases compared with controls, this may suggest that Ze 185 could be a viable option to substitute benzodiazepines in patients suffering from depression and anxiety symptoms. However, to substantiate this hypothesis, a direct comparison study between benzodiazepines and Ze 185 would be necessary.Significantly less cases than controls received prescriptions of benzodiazepines (cases n = 661, controls n = 809). The number of patients with prescribed hypnotics/sedatives was significantly higher for cases than controls (cases n = 940, controls n = 603). In the group of hypnotics/sedatives, the main differences were seen for a specific valerian/hops extract (Ze 91019). Significantly more cases than controls received a prescription of this fixed extract combination (cases n = 784, controls n = 444). The number of patients receiving antidepressant prescriptions was also significantly increased among cases compared with controls
https://www.imrpress.com/journal/FBL/28/6/10.31083/j.fbl2806111/htm1Overall, these results indicate that Petasites hybridus L. root extract selectively acts as a pro-oxidant in breast cancer cells and thus represents a potential therapeutic option for cancer treatment with fewer side effects.We previously demonstrated selective cytotoxic effects and morphological changes associates with apoptosis in MCF-7 and MDA-MB-231 breast cancer cells after exposure to a standardized root extract of the medicinal plant Petasites hybridus L. with active sesquiterpenes termed petasins [16]. Common butterbur and its bioactive components are well-studied for treatment of migraine and other disorders, but their potential anti-tumor activity remains poorly investigated
https://pubmed.ncbi.nlm.nih.gov/15623680/1Over 4 months of treatment, in the per-protocol analysis, migraine attack frequency was reduced by 48% for Petasites extract 75 mg he proportion of patients with a > or =50% reduction in attack frequency after 4 months was 68% for patients in the Petasites extract 75-mg arm
https://www.ncbi.nlm.nih.gov/books/NBK74697/1Three placebo-controlled studies found that P. hybridus may be effective for relief of symptoms or improved peak nasal inspiratory flow. Two studies that compared P. hybridus with non-sedating antihistamine and one that comparing it with placebo found no significant differences between treatments for any outcomes. There was encouraging evidence for Petasites hybridus as a treatment for seasonal allergic rhinitis, but financially independent replication of the results was needed
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471736/1the present study was the first to isolate and screen material from PJ [Butterbur] and examine its potent anticancer activity. In vitro methods, including a cell proliferation assay and cell cycle analysis, were used to demonstrate that PJE induces apoptosis and suppresses the Akt/mTOR and Wnt signaling pathways by reducing the expression levels of β-catenin, p-Akt, p-mTOR and p-GSK3β. In addition, the in vivo experiments further confirmed that PJE suppressed the Akt/mTOR and Wnt signaling pathways. Therefore, these observations highlight the potential value of PJE as an anticancer agent.The results revealed that PJE significantly suppressed the expression levels of p-mTOR, p-Akt, β-catenin and p-GSK3β. In addition, pretreatment with rapamycin and LY294002, which are specific inhibitors of mTOR and PI3K, respectively, followed by PJE treatment, effectively reduced the expression levels of β-catenin and phosphorylated mTOR, Akt and GSK3β (Fig. 4A). As shown in Fig. 4B, suppression of key molecules in the Wnt signaling pathway by PJE led to decreased growth of HCC cells. In addition, β-catenin and p-GSK3β were suppressed further when simultaneously treated with inhibitors such as XAV 939 or BIO, which are specific inhibitors of β-catenin and GSK3β. These results suggest that PJE may significantly suppress the expression levels of p-mTOR, p-Akt, β-catenin and p-GSK3β.Screenshot from 2024-01-23 12-27-08
https://www.jci.org/articles/view/139933#SEC11PT treatment significantly inhibited the formation of lung metastatic colonies in both spontaneous metastatic and i.v. injection models. This effect was likely due to ETCC1 inhibition and its subsequent events, including energy depletion, cytoskeletal remodeling, focal adhesion inhibition, oncoprotein downregulation, and cell-cycle arrest. Particularly, PT treatment induced depletion of ATP, an energy source for all metastatic steps, including invasion, extravasation, and colonization. Tumor cells flexibly utilize both glycolysis and OXPHOS for ATP production; however, PT treatment defunctionalized OXPHOS-mediated ATP production and made tumor cells highly dependent on glycolysis for their ATP production. Such tumor cells easily demonstrated ATP depletion under the low-glucose condition. Given that glucose is typically less available in the tumor microenvironment (36), the loss of flexibility for ATP production could critically impair the metastatic potential of the tumor cells in vivo.Furthermore, we evaluated its antimetastatic potential in the Jyg-MCB (mouse metastatic mammary cancer) spontaneous metastatic model, in which mice developed lung and lymph node metastasis from the sites of the s.c.-injected cells. Mice were s.c. injected with Jyg-MCB cells and 24 days thereafter, they received i.p.-delivered PT at 50 mg/kg for a total of 6 times over a 16-day period (Figure 10C). As a result, we found that PT treatment also significantly inhibited metastasis to the lungs and lymph nodes (Figure 10, D–H and Supplemental Figure 16A). Immunohistochemical analysis revealed that the mice administered with PT had fewer p-FAKY397–positive lung metastatic colonies, as well as a lower positive percentage of cell cycle–related proteins Screenshot from 2024-01-23 14-43-13

Help grow the community

Join the Pubmedders subscriber base

Get our monthly email newletter – designed so you can give us your opinions, thoughts and feedback…

ALL contributions are invested into growing the site to help others.